| 摘要 |
<p>The present invention relates to new dopamine D<sub>3</sub> and D<sub>2 </sub>and serotonin 5-HT<sub>1A</sub> receptor subtype preferring ligands of formula (I); wherein A represents alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or a group of formula -NR<sub>1</sub>R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> represent independently a substituent selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl or cycloalkyl or R<sub>1</sub> and R<sub>2</sub> form with the adjacent nitrogen atom and optionally with further heteroatom(s) a heterocyclic ring; m is an integer of 0 to 1 ; n is an integer of 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmacological compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine and/or 5-HT<sub>1A</sub> receptors.</p> |
